A day after a study in the journal Lancet challenged the long-standing notion that raising levels of HDL — commonly known as “good” cholesterol — prevents heart attacks, top cardiology experts differed on whether the research really means the end of the road for therapies aimed at boosting HDL levels to beat back heart disease.
Some, like Dr. Philip Greenland, said the new evidence may very well close the book on such efforts.
One type is safer than the other
Heart disease is the leading cause of death in individuals with chronic kidney disease.
Newswise — Washington, DC (May 17, 2012) — One type of open heart surgery is likely safer than the other for chronic kidney disease (CKD) patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
LOS ANGELES – Conservative commentator and website editor Andrew Breitbart died of heart failure and had up to a 60 percent narrowing of a major artery, a Los Angeles County coroner’s office report released Wednesday said.
The office ruled that the cause of Breitbart’s death was heart failure and hypertrophic cardiomyopathy with focal coronary atherosclerosis, or hardening of the arteries.
By Carolyn Y. Johnson and Deborah Kotz, Globe Staff
Raising levels of “good” cholesterol may not be so good for you after all. A study published Wednesday by Boston-area scientists challenges the long-held idea that HDL cholesterol actively protects against heart disease, finding that people with genes that boosted their HDL did not have a lowered risk of heart attacks.
In the study appearing in the medical journal The Lancet, a team led by researchers from Massachusetts General Hospital and the Broad Institute examined the health of more than 100,000 people, some of them with genetic variations that elevated their levels of HDL, and found that those variations did not protect against heart attacks.
Loading ...